LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc.?(NASDAQ:?INMB) (the ?Company?),?an immunology company developing treatments that harness the patient?s innate immune system to fight disease, today reported its financial results for the third quarter ended September 30, 2019 and is providing a business update.
News
INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member
LA JOLLA, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, is pleased to announce that Edgardo (Ed) Bar… […]
News
INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE
LA JOLLA, Calif., June 27, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments that harness the patient?s innate immune system to fight disease, announced today that the peer-reviewed open access s… […]
News
INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results
LA JOLLA, Calif, July 31, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today… […]
